About NovaPharm
Strategic pharmaceutical opportunities begin with evidence.
Oncology, specialty, oral-liquid and selected licensed-medicine opportunities remain subject to rights, evidence, authorisation and confirmed availability.
01Oncology and specialty
Continuity requires product-specific operating discipline.
Source, formulation, demand, storage, documentation and market-access requirements are evaluated together before a category is treated as commercially actionable.
Explore oncology continuity02Oral liquids
Technical feasibility and commercial viability must agree.
Formulation, packaging, batch size, shelf life, transfer responsibilities and approved market status remain product-specific decisions.
Discuss a product opportunity03Evidence boundary
A category is not a stock or availability claim.
NovaPharm does not publish price, inventory, licence or supply claims unless the relevant evidence and operating authority have been accepted.
Review the regulatory modelStart a qualified conversation